Chronic Intermittent Hypoxia Increases Cell Proliferation in Hepatocellular Carcinoma.
DEN-induced rat model
cell proliferation
hepatocellular carcinoma
intermittent hypoxia
obstructive sleep apnea syndrome
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
28 06 2022
28 06 2022
Historique:
received:
27
05
2022
revised:
14
06
2022
accepted:
24
06
2022
entrez:
9
7
2022
pubmed:
10
7
2022
medline:
14
7
2022
Statut:
epublish
Résumé
Obstructive sleep apnea (OSA) syndrome is characterized by chronic intermittent hypoxia and is associated with an increased risk of all-cause mortality, including cancer mortality. Hepatocellular carcinoma (HCC) is the most common type of liver cancer, characterized by increasing incidence and high mortality. However, the link between HCC and OSA-related chronic intermittent hypoxia remains unclear. Herein, we used a diethylnitrosamine (DEN)-induced HCC model to investigate whether OSA-related chronic intermittent hypoxia has an impact on HCC progression. To elucidate the associated mechanisms, we first evaluated the hypoxia status in the DEN-induced HCC model. Next, to simulate OSA-related intermittent hypoxia, we exposed cirrhotic rats with HCC to intermittent hypoxia during six weeks. We performed histopathological, immunohistochemical, RT-qPCR, and RNA-seq analysis. Chronic DEN injections strongly promoted cell proliferation, fibrosis, disorganized vasculature, and hypoxia in liver tissue, which mimics the usual events observed during human HCC development. Intermittent hypoxia further increased cell proliferation in DEN-induced HCC, which may contribute to an increased risk of HCC progression. In conclusion, our observations suggest that chronic intermittent hypoxia may be a factor worsening the prognosis of HCC.
Identifiants
pubmed: 35805134
pii: cells11132051
doi: 10.3390/cells11132051
pmc: PMC9265377
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Nat Rev Clin Oncol. 2022 Jan;19(1):23-36
pubmed: 34508258
Am J Respir Crit Care Med. 2011 Sep 15;184(6):724-31
pubmed: 21680945
Genome Biol. 2014;15(12):550
pubmed: 25516281
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Hepatol. 2012 Jan;56(1):225-33
pubmed: 21703181
Sci Rep. 2019 Mar 4;9(1):3369
pubmed: 30833661
Genome Biol. 2010;11(10):R106
pubmed: 20979621
J Clin Sleep Med. 2014 Apr 15;10(4):355-62
pubmed: 24733978
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Int J Mol Sci. 2020 Nov 20;21(22):
pubmed: 33233617
Oncogene. 2018 Aug;37(31):4214-4225
pubmed: 29713057
Nat Rev Dis Primers. 2021 Jan 21;7(1):6
pubmed: 33479224
Bioinformatics. 2015 Jan 15;31(2):166-9
pubmed: 25260700
Am J Respir Crit Care Med. 2012 Jul 15;186(2):190-4
pubmed: 22610391
Chest. 2020 Dec;158(6):2610-2620
pubmed: 32629036
PLoS One. 2016 Jun 09;11(6):e0157022
pubmed: 27280887
Eur Respir J. 2012 Jan;39(1):215-7
pubmed: 22210813
Cells. 2022 Feb 05;11(3):
pubmed: 35159368
Biochem Biophys Rep. 2017 Jul 19;11:130-137
pubmed: 28955777
Cell. 2016 Mar 24;165(1):35-44
pubmed: 26997480
Int J Mol Sci. 2021 Nov 29;22(23):
pubmed: 34884703
Oncotarget. 2018 Jan 23;9(13):11145-11158
pubmed: 29541403
J Hepatol. 2016 Sep;65(3):560-9
pubmed: 27501738
Sci Rep. 2020 Feb 5;10(1):1854
pubmed: 32024881
Cancers (Basel). 2021 Oct 04;13(19):
pubmed: 34638465
Int J Mol Sci. 2019 Sep 25;20(19):
pubmed: 31557884
Eur Respir J. 2020 Jan 9;55(1):
pubmed: 31649063
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
J Appl Physiol (1985). 2021 Jun 1;130(6):1955-1960
pubmed: 33955265
Respir Physiol. 1999 Sep 1;117(1):53-8
pubmed: 10505479
Eur Respir J. 2018 Jun 28;51(6):
pubmed: 29880653
J Transl Med. 2020 Sep 4;18(1):342
pubmed: 32887635
J Transl Med. 2021 May 1;19(1):186
pubmed: 33933107
Obesity (Silver Spring). 2016 Apr;24(4):871-7
pubmed: 26880657
Am J Physiol Regul Integr Comp Physiol. 2012 Oct 1;303(7):R700-9
pubmed: 22895743
Mol Cancer Ther. 2017 Oct;16(10):2157-2165
pubmed: 28566435
Chest. 2015 Jan;147(1):266-274
pubmed: 25560865
Oncotarget. 2017 Jun 27;8(37):61592-61603
pubmed: 28977888
PLoS One. 2017 Jun 8;12(6):e0179444
pubmed: 28594929